Drug Profile
Immune globulin - Shanxi Kangbao Biological Product
Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Shanxi Kangbao Biological Product
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Varicella zoster virus infections
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Varicella zoster virus infections in China (unspecified route), prior to August 2023 (Shanxi Kangbao Biological Product pipeline, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Varicella-zoster-virus-infections in China
- 14 Jan 2016 Preclinical trials in Varicella zoster virus infections in China (unspecified route) prior to January 2016 (Shanxi Kangbao Biological Product pipeline, January 2016)